Pierre Roger Dubus

Pierre Roger Dubus

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Cancer Cell
Verified
Journal Article
Closed access
CGCarmen Guerra
Carmen Guerra
ASAlberto J. Schuhmacher
Alberto J. Schuhmacher
MCMarta Cañamero
Marta Cañamero
PGPaul J. Grippo
Paul J. Grippo
LVLena Verdaguer
Lena Verdaguer
MBMariano Barbacid
Mariano Barbacid

16 August 2007 in Nature
Verified
Journal Article
Closed access
PDF file
DSDavid Santamaría
David Santamaría
CBCédric Barrière
Cédric Barrière
ACAntonio Cerqueira
Antonio Cerqueira
SHSarah Hunt
Sarah Hunt
CTClaudine Tardy
Claudine Tardy
MBMariano Barbacid
Mariano Barbacid

1 August 2004 in Cell
Verified
Journal Article
Closed access
MMMarcos Malumbres
Marcos Malumbres
RDRocio DKFZ
Rocio DKFZ
DSDavid Santamarı́a
David Santamarı́a
JGJavier Galán
Javier Galán
ACAna Cerezo
Ana Cerezo
MBMariano Barbacid
Mariano Barbacid

1 May 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SRSushil G. Rane
Sushil G. Rane
PDPierre Roger Dubus
Pierre Roger Dubus
RMRichard V. Mettus
Richard V. Mettus
EGElizabeth J. Galbreath
Elizabeth J. Galbreath
GBGuenther Boden
Guenther Boden
MBMariano Barbacid
Mariano Barbacid

1 August 2003 in Cancer Cell
Verified
Journal Article
Closed access
CGCarmen Guerra
Carmen Guerra
NMNieves Mijimolle
Nieves Mijimolle
ADAlma Dhawahir
Alma Dhawahir
PDPierre Roger Dubus
Pierre Roger Dubus
MBMarta Barradas
Marta Barradas
MBMariano Barbacid
Mariano Barbacid

4 May 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ABAnais BRIOT
Anais BRIOT
CDCéline Deraison
Céline Deraison
MLMatthieu Lacroix
Matthieu Lacroix
CBChrystelle Bonnart
Chrystelle Bonnart
ARAurélie Robin
Aurélie Robin
AHAlain HOVNANIAN
Alain HOVNANIAN
Netherton syndrome (NS) is a severe genetic skin disease with constant atopic manifestations that is caused by mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor lymphoepithelial Kazal-type–related inhibitor (LEKTI). Lack of LEKTI causes stratum corneum detachment secondary to epidermal proteases hyperactivity. This skin barrier defect favors allergen absorption and is generally regarded as the underlying cause for atopy in NS. We show for the first time that the pro-Th2 cytokine thymic stromal lymphopoietin (TSLP), the thymus and activation-regulated chemokine, and the macrophage-derived chemokine are overexpressed in LEKTI-deficient epidermis. This is part of an original biological cascade in which unregulated kallikrein (KLK) 5 directly activates proteinase-activated receptor 2 and induces nuclear factor κB–mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor α, and IL8. This proinflammatory and proallergic pathway is independent of the primary epithelial failure and is activated under basal conditions in NS keratinocytes. This cell-autonomous process is already established in the epidermis of Spink5−/− embryos, and the resulting proinflammatory microenvironment leads to eosinophilic and mast cell infiltration in a skin graft model in nude mice. Collectively, these data establish that uncontrolled KLK5 activity in NS epidermis can trigger atopic dermatitis (AD)–like lesions, independently of the environment and the adaptive immune system. They illustrate the crucial role of protease signaling in skin inflammation and point to new therapeutic targets for NS as well as candidate genes for AD and atopy.